A new formulation of fenofibrate: suprabioavailable tablets.
The rationale for, and development of, a new suprabioavailable fenofibrate tablet formulation is described. The new suprabioavailable tablet formulation combines well-established micronisation technology with a new micro-coating process. The new formulation provides more predictable and reliable drug absorption. Owing to the strong relationship between the fenofibrate dissolution performance and its oral bioavailability, equivalent plasma levels of active principal are achieved at a lower dose, with less inter-subject variability and a reduced food effect. The new suprabioavailable tablet may, therefore, be a more efficient and better tolerated formulation.
Guichard
J P
JP
Laboratoires Fournier, Fontaine les Dijon, Daix, France.
Blouquin
P
P
Qing
Y
Y
D001682:Biological Availability; D011345:Fenofibrate / Q000493:pharmacokinetics*; D006801:Humans; D000960:Hypolipidemic Agents / Q000493:pharmacokinetics*; D012995:Solubility; D013607:Tablets / Q000493:pharmacokinetics
D000960:Hypolipidemic Agents; D013607:Tablets; D011345:Fenofibrate